Isofol publishes prospectus in connection with the fully guaranteed preferential rights issue of approximately SEK 400 million 1
 Isofol Medical AB’s (publ), Board of Directors resolved on May 18, 2021, on an issue of shares of a maximum of 62,524,474 shares with preferential rights for the Company’s existing shareholders (the “Rights Issue”). If the Rights Issue is fully subscribed, the Company will receive approximately SEK 400 million before transaction costs related to the Rights Issue. In connection with the Rights Issue, the Company publishes a prospectus which today has been approved and registered by the Swedish Financial Supervisory Authority (Sw. Finansinspektionen).

Not for publication, distribution or release, directly or indirectly, in whole or in part, within or into the United Kingdom, US, CanadaJapanAustraliaHong KongNew Zealand or any other jurisdiction in which such publication, distribution or release may be contravening to any applicable laws or rules. Additional restrictions are applicable, please see “Important information” in the end of this press release.

Timetable for the Rights Issue

                                   

                                   

                                   

Record date for participation in the Rights Issue

                                   

                                   

                                   

May 25, 2021

                                   

                                               

                                   

                                   

Subscription period

                                   

                                   

                                   

May 27 – June 10, 2021

                                   

                                               

                                   

                                   

Trading in subscription rights

                                   

                                   

                                   

May 27 – June 7, 2021

                                   

                                               

                                   

                                   

Trading in BTAs

                                   

                                   

                                   

May 27 – June 14, 2021

                                   

                                               

                                   

                                   

Announcement of final outcome in the Rights Issue

                                   

                                   

                                   

Around June 14, 2021

                                   

                                               

                                   

                                   

Delivery of and trading in new shares subscribed with subscription rights

                                   

                                   

                                   

Around June 18, 2021

                                   

                                               

                                                      

Delivery of and trading in new shares subscribed without subscription rights

                                   

                                   

                                   

Around June 30, 2021

                                   

                                   

Prospectus

For full information regarding the Rights Issue, please refer to the prospectus, which is available on Isofol’s website, www.isofolmedical.com. Link to the application form is available on the same link at the start of the subscription period at the latest, and on Carnegie Investment Bank AB (publ)’s website, www.carnegie.se. The prospectus is also available on the Swedish Financial Supervisory Authority’s (Sw. Finansinspektionen) website, www.fi.se.

Advisors

Carnegie Investment Bank AB (publ) and Pareto Securities AB act as Joint Bookrunners in connection with the Rights Issue. Vinge law firm acts as legal adviser to Isofol, and Schjødt law firm acts as legal adviser to the Joint Bookrunners. Ashurst LLP acts as legal adviser to the Joint Bookrunners as to US securities law.

For further information, please contact

Isofol Medical AB (publ)
Jarl Ulf Jungnelius, M.D., Chief Executive Officer
E-mail: jungnelius@isofolmedical.com
Mobil: +46 (0) 709 16 89 55

Certified Adviser
FNCA Sweden AB
E-mail: info@fnca.se
Phone: +46 (0)8 528 003 99

See Campaign: http://isofolmedical.com
Contact Information:
Isofol Medical AB (publ)
Jarl Ulf Jungnelius, M.D., Chief Executive Officer
E-mail: jungnelius@isofolmedical.com
Mobil: +46 (0) 709 16 89 55

Tags:
, Wire, Legal Newswire, United States, English